

Recbio and Rongsheng Biotech collaborate over a new Adjuvant Vaccine Project in China

27 March 2024 | News

The two parties signed a strategic cooperation agreement on the new adjuvant vaccine project



Two Chinese firms, Jiangsu Recbio Technology Co., Ltd. and Shanghai Rongsheng Biotech Co., Ltd. have partnered to lead a new adjuvant vaccine research and development project in Shanghai. The partnership facilitates the joint development of new adjuvant vaccines.

The two parties signed a strategic cooperation agreement on the new adjuvant vaccine project. Recbio will provide its new adjuvant independently developed based on the new adjuvant technology platform, and Rongsheng Biotech will provide its independently designed viral antigen. This project will empower existing Rongsheng Biotech vaccines under development with new adjuvants to improve immunogenicity and optimize the vaccination program.

Dr. Liu Yong, founder, chairman of the board and general manager of Recbio, said: "This cooperation is an important milestone for Recbio adjuvants to empower industry chain partners. New adjuvant play a crucial role in the development and application of innovative vaccines. Relying on its independently developed new adjuvant technology platform."

Zhu Shaorong, founder and chairman of Rongsheng Biotech, said: "Rongsheng Biotech has built a key core technology platform for 'virus + bacteria' vaccines based on independent innovation and research and development. It has large-scale production capabilities and has achieved technological innovation and upgrade breakthroughs in scientific research on a number of vaccine products under development."